KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

High-dose chemotherapy for relapsed testicular germ cell tumours.

Michal Chovanec, Nabil Adra, Mohammad Abu Zaid, Rafat Abonour, Lawrence Einhorn

Nat Rev Urol 20(4) 217-225

PMID36477219
PMCID-
DOI10.1038/s41585-022-00683-1
发表日期2022-12-08
摘要

摘要

Relapsed testicular germ cell tumours (GCTs) might be cured with salvage chemotherapy. Accepted salvage treatment is conventional-dose chemotherapy (CDCT) or high-dose chemotherapy (HDCT). HDCT with peripheral blood stem cell transplant might produce a higher number of durable responses than CDCT. We discuss studies reporting on outcomes of salvage HDCT in relapsed GCTs. The most reproducible results were achieved with HDCT with two cycles of etoposide and carboplatin or three cycles of the paclitaxel, ifosfamide, carboplatin and etoposide regime. Using these two regimens, sustained cure rates of 50-66% were reported in phase I, phase II and retrospective studies published in the past two decades. Cure rates in patients with cisplatin-resistant disease are between 30% and 45%. Two phase III randomized studies were conducted with certain limitations and were unsuccessful in showing a survival benefit of HDCT. Thus, salvage treatment remains a controversial topic. Salvage HDCT with peripheral blood stem cell transplant and CDCT are two recommended treatment options for relapsed GCTs. Consistently reported cure rates from phase I, phase II and large retrospective studies support the use of HDCT in the hands of an experienced team of oncologists.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。